deltatrials
Unknown PHASE3 NCT00003679

Combination Chemotherapy in Treating Women With Breast Cancer

A Randomised Comparative Trial of Adriamycin + Taxotere vs. Adriamycin + Cyclophosphamide as Primary Medical Therapy for Patients With Potentially Operable Breast Cancer Greater Than or Equal to 3 cm Diameter, Locally Advanced, or Inflammatory Disease

Sponsor: Scottish Cancer Therapy Network

Conditions Breast Cancer
Interventions conventional surgery cyclophosphamide docetaxel doxorubicin hydrochloride radiation therapy tamoxifen citrate
Updated 5 times since 2017 Last updated: Nov 5, 2013 Started: Nov 30, 1998

A PHASE3 clinical study on Breast Cancer, this trial is ongoing. The trial is conducted by Scottish Cancer Therapy Network and has accumulated 5 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE3

    First recorded

Nov 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Scottish Cancer Therapy Network
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Glasgow, United Kingdom